Skip to content

Mindfulness-Based Therapy for Interstitial Cystitis/Bladder Pain Syndrome

Mindfulness-Based Therapy for Interstitial Cystitis/Bladder Pain Syndrome

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02457182
Enrollment
20
Registered
2015-05-29
Start date
2014-11-30
Completion date
2015-06-30
Last updated
2018-10-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Complementary Medicine, Interstitial Cystitis, Mindfulness, Painful Bladder Syndrome

Brief summary

Interstitial cystitis/bladder pain syndrome (IC/BPS) is a poorly understood disease with unreliable treatments. Although it is not known what causes it for certain, we do know that life stressors may make the disease worse or cause flares. Mindfulness Based Stress Reduction (MBSR) is an 8 week class focused on meditation and other techniques that the investigators think may be helpful to people with IC/BPS. This trial will assign participants to an MBSR class or usual care for their IC/BPS to see if the MBSR class would be helpful for their disease.

Detailed description

BACKGROUND/SCIENTIFIC RATIONALE Interstitial cystitis/bladder pain syndrome (IC/BPS) is associated with significant morbidity and poorly understood underlying pathophysiology. IC/BPS comprises a symptom complex defined by the American Urological Association (AUA) as An unpleasant sensation (pain, pressure, discomfort) perceived to be related to the urinary bladder, associated with lower urinary tract symptoms of more than six weeks duration, in the absence of infection or other identifiable causes(1). Up to 11% of women are affected by IC/BPS (2), and the disorder may be significantly underdiagnosed (3). A 2008 study (4) indicated that 43% of patients with IC/BPS require multimodal therapy with an average of 7-12 yearly clinic visits at a cost of $9,000/patient. Twenty percent of women report wage losses of \>$4000 per year (5). Current theories for the cause of IC/BPS include infectious agents, a defective uroepithelium permeable to toxic substances, structural abnormalities, neurogenic inflammation, increased neurologic sensitivity, or an allergic response involving increased numbers of bladder mast cells (6). Despite these theories, reliable treatments remain elusive. Most IC/BPS treatments target one of these proposed mechanisms, involve trial and error of several therapies (1), and often utilize multiple modalities (7). Treatment success ranges from 47-93% for intravesical instillation to 21-64% for oral therapies, with discontinuation rates up to 80% due to intolerable side effects (1). Efficacious treatments for IC/BPS that apply to a greater proportion of patients with limited side effects are urgently needed. Mindfulness Based Stress Reduction (MBSR), a Complementary Alternative Medicine (CAM)-based therapy, potentially fulfills this need. The Interstitial Cystitis Association (ICA), a patient-led organization, sponsored a survey of 2100 IC/BPS patients. They reported that 84% had tried CAM therapy and 55% of those surveyed reported that their physicians had recommended CAM (8). According to a 2007 National Health Interview survey (9), CAM is used by 38% of adults in the United States. MBSR has been successfully employed to treat chronic pain syndromes and has been used in disorders such as multiple chemical sensitivity, chronic fatigue syndrome, fibromyalgia (10), and irritable bowel syndrome (IBS) (11). These disorders may coexist in patients with IC/BPS (6). In IC/BPS, increases in stress are positively correlated with increased pain (12); and one study reported that up to 80% of IC/BPS patients found stress reduction decreased their symptoms (8). MBSR was found to be efficacious in the treatment of urgency urinary incontinence, a urinary disorder closely related to IC/BPS (13, 14). While MBSR has shown therapeutic promise in conditions that are similar to or coexist with IC/BPS, and has been rated as helpful by patients suffering from IC/BPS, rigorous randomized clinical trials investigating the efficacy of this intervention are lacking (8). OBJECTIVES/AIMS/HYPOTHESES Ultimately, the investigators long-term goal is to provide a much-needed treatment for IC/BPS using patient-centered therapy such as MBSR. The objective of this research is to conduct a pilot RCT to explore whether MBSR is acceptable to patients and results in improved symptoms when added to IC/BPS 1st and 2nd-line treatments as recommended in the American Urological Association guidelines (see Table 1). The investigators hypothesize that an 8-week MBSR class will be acceptable to IC/BPS patients and that MBSR used in conjunction with traditional 1st and 2nd line therapies will improve symptoms compared to IC/BPS patients using traditional 1st and 2nd line therapies alone. If this pilot study demonstrates effectiveness and acceptance of MBSR, it would provide data to justify a larger randomized controlled trial. If the investigators' hypothesis is supported with this exploratory study, MBSR, an understudied and potentially underutilized therapy, will expand treatment options for IC/BPS patients. The investigators' aims in pursuit of this goal are; Aim #1: To determine whether the addition of MBSR to 1st and 2nd line therapies as recommended by AUA guidelines improves IC/BPS symptoms as measured by the primary outcome the Global Response Assessment (GRA), as well as the O'Leary-Sant Symptom and Problem Index (OSPI), and Visual Analog (VAS) pain scale. Hypothesis: The investigators hypothesize that MBSR will be an effective treatment for IC/BPS as measured by the validated GRA, O'Leary-Sant and VAS pain scales. Aim #2: To evaluate whether participation in a structured MBSR class will improve quality of life, sexual function and overall self-efficacy in patients with IC/BPS, based on changes in the Short Form Health Survey (SF-12), Female Sexual Function Index (FSFI), and the Pain Self-Efficacy Scale (SES). Hypothesis: The investigators' hypothesize that MBSR will improve quality of life, sexual function and impressions of self-efficacy as measured by these validated scales

Interventions

OTHERMindfulness-based Stress Reduction (MBSR)
OTHERUsual medical therapy

Sponsors

University of New Mexico
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Actively utilizing but are incomplete responders to the AUA guideline's 1st or 2nd line therapies * Non-pregnant women ≥18 years old * Meets IC/BPS diagnosis by AUA guidelines, OSPI \>8 * Negative UA or Urine Culture at time of diagnosis or within 2 months if no change in symptoms over that period * Able to speak and understand English * Currently undergoing 1st or 2nd-line treatment as per AUA guidelines, for at least 4 weeks duration

Exclusion criteria

* Untreated Urinary tract infection * Unevaluated Hematuria * Urinary retention * Pregnant or lactating women * History of cystectomy, augmentation cystoplasty or urinary diversion * History of cystitis potentially due to pelvic radiation or Cytoxan * Inability to speak and understand English * Either treatment naïve for IC/BPS or on 3rd line or higher treatment per AUA guidelines

Design outcomes

Primary

MeasureTime frameDescription
Global Response Assessment (GRA)Within 2 weeks of 8-week class endingThe GRA is a 7-point scale, with scores ranging from markedly, moderately or slightly worse to slightly, moderately or markedly improved. This measure is used in many types of research and is not specific to IC/BPS.

Secondary

MeasureTime frameDescription
O'Leary Sant Symptom Problem Index (OSPI)Baseline and within 2 weeks of 8-week class endingThe OSPI is a Interstitial cystitis (IC/BPS)-specific scale composed of the symptom index and problem index as well as a total, which sums the symptom and problem scores caused by IC/BPS. Symptom scores range from 0-21. Problem scores range from 0-16 Higher scores indicate a worse condition. Total scores range 0-37, with higher scores indicating a worse condition.
Visual Analog (VAS) Pain ScaleBaseline and within 2 weeks of 8-week class endingThe VAS scale is a 10-point scale ranging from 0 (no pain) to 10 (unbearable pain). 0 is considered better while 10 is considered worse.
Short Form Health Survey (SF-12)Baseline and within 2 weeks of 8-week class endingThe short form health survey (SF-12) is a scale used to evaluate chronic conditions. It is composed of a mental component and physical component. Each is made up of 12 questions totaling a score of 100 points. A zero score indicates the lowest level of health measured and 100 indicates the highest level of health.
Female Sexual Function Index (FSFI)Baseline and within 2 weeks of 8-week class endingThe FSFI measures sexual function. It is composed of 6 individual domain scores (desire, arousal, lubrication, orgasm, satisfaction and pain), which are summed to create a total score. Higher scores indicate better sexual function. Ranges: Desire 2-10 Arousal 0-20 Lubrication 0-20 Orgasm 0-15 Satisfaction 2-15 Pain 0-15 Total score ranges from 4-95 and is calculated by adding the 6 domains together. Again, higher scores indicate better sexual function.
Pain Self-Efficacy Scale (PSEQ)Baseline and within 2 weeks of 8-week class endingThe PSEQ is a scale describing how patients rate their abilities to complete daily activities. It is a 60 point scale (scores range from 0-60) composed of 10 questions. Higher numbers signify better functioning or less limit by disease. A total score is calculating by summing individual items.

Countries

United States

Participant flow

Participants by arm

ArmCount
Mindfulness-based Stress Reduction (MBSR)
Will receive usual care continuing current treatments in addition to MBSR Mindfulness-based Stress Reduction (MBSR) Usual medical therapy
9
Usual Care
Will receive usual care and continue current treatments Usual medical therapy
11
Total20

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyLost to Follow-up10

Baseline characteristics

CharacteristicMindfulness-based Stress Reduction (MBSR)Usual CareTotal
Age, Continuous46.3 years
STANDARD_DEVIATION 15.2
44.4 years
STANDARD_DEVIATION 13.9
45.3 years
STANDARD_DEVIATION 14.1
BMI (kg/m^2)28.0 kg/m^2
STANDARD_DEVIATION 9.2
26.4 kg/m^2
STANDARD_DEVIATION 6
27.1 kg/m^2
STANDARD_DEVIATION 7.3
Race
American Indian/Alaskan Native
0 participants2 participants2 participants
Race
Asian
0 participants1 participants1 participants
Race
Caucasian
9 participants5 participants14 participants
Race
Other
0 participants3 participants3 participants
Region of Enrollment
United States
9 participants11 participants20 participants
Sex: Female, Male
Female
9 Participants11 Participants20 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants
Time with IC diagnosis5.0 years
STANDARD_DEVIATION 5.3
3.85 years
STANDARD_DEVIATION 5.1
4.3 years
STANDARD_DEVIATION 4.96
Time with IC symptoms9.6 years
STANDARD_DEVIATION 9.9
8.9 years
STANDARD_DEVIATION 7.1
9.2 years
STANDARD_DEVIATION 8.3

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 90 / 11
serious
Total, serious adverse events
0 / 90 / 11

Outcome results

Primary

Global Response Assessment (GRA)

The GRA is a 7-point scale, with scores ranging from markedly, moderately or slightly worse to slightly, moderately or markedly improved. This measure is used in many types of research and is not specific to IC/BPS.

Time frame: Within 2 weeks of 8-week class ending

ArmMeasureGroupValue (NUMBER)
Mindfulness-based Stress Reduction (MBSR)Global Response Assessment (GRA)At least moderately improved1 participants
Mindfulness-based Stress Reduction (MBSR)Global Response Assessment (GRA)Markedly Improved2 participants
Mindfulness-based Stress Reduction (MBSR)Global Response Assessment (GRA)At least slightly improved7 participants
Mindfulness-based Stress Reduction (MBSR)Global Response Assessment (GRA)No improvement1 participants
Usual CareGlobal Response Assessment (GRA)No improvement7 participants
Usual CareGlobal Response Assessment (GRA)At least slightly improved4 participants
Usual CareGlobal Response Assessment (GRA)Markedly Improved0 participants
Usual CareGlobal Response Assessment (GRA)At least moderately improved3 participants
Secondary

Female Sexual Function Index (FSFI)

The FSFI measures sexual function. It is composed of 6 individual domain scores (desire, arousal, lubrication, orgasm, satisfaction and pain), which are summed to create a total score. Higher scores indicate better sexual function. Ranges: Desire 2-10 Arousal 0-20 Lubrication 0-20 Orgasm 0-15 Satisfaction 2-15 Pain 0-15 Total score ranges from 4-95 and is calculated by adding the 6 domains together. Again, higher scores indicate better sexual function.

Time frame: Baseline and within 2 weeks of 8-week class ending

ArmMeasureGroupValue (MEAN)Dispersion
Mindfulness-based Stress Reduction (MBSR)Female Sexual Function Index (FSFI)Arousal after3.3 units on a scaleStandard Deviation 2.3
Mindfulness-based Stress Reduction (MBSR)Female Sexual Function Index (FSFI)Orgasm after2.5 units on a scaleStandard Deviation 2.5
Mindfulness-based Stress Reduction (MBSR)Female Sexual Function Index (FSFI)Desire before2.9 units on a scaleStandard Deviation 1.6
Mindfulness-based Stress Reduction (MBSR)Female Sexual Function Index (FSFI)Desire after3.5 units on a scaleStandard Deviation 1.6
Mindfulness-based Stress Reduction (MBSR)Female Sexual Function Index (FSFI)Arousal before2.6 units on a scaleStandard Deviation 2.1
Mindfulness-based Stress Reduction (MBSR)Female Sexual Function Index (FSFI)Lubrication before3.2 units on a scaleStandard Deviation 2.7
Mindfulness-based Stress Reduction (MBSR)Female Sexual Function Index (FSFI)Lubrication after3.4 units on a scaleStandard Deviation 2.4
Mindfulness-based Stress Reduction (MBSR)Female Sexual Function Index (FSFI)Orgasm before3.0 units on a scaleStandard Deviation 2.7
Mindfulness-based Stress Reduction (MBSR)Female Sexual Function Index (FSFI)Satisfaction before2.8 units on a scaleStandard Deviation 2.3
Mindfulness-based Stress Reduction (MBSR)Female Sexual Function Index (FSFI)Satisfaction after3.8 units on a scaleStandard Deviation 1.9
Mindfulness-based Stress Reduction (MBSR)Female Sexual Function Index (FSFI)Pain before2.5 units on a scaleStandard Deviation 2.4
Mindfulness-based Stress Reduction (MBSR)Female Sexual Function Index (FSFI)Pain after3.1 units on a scaleStandard Deviation 2.6
Mindfulness-based Stress Reduction (MBSR)Female Sexual Function Index (FSFI)Total before16.7 units on a scaleStandard Deviation 12.8
Mindfulness-based Stress Reduction (MBSR)Female Sexual Function Index (FSFI)Total after19.5 units on a scaleStandard Deviation 12
Usual CareFemale Sexual Function Index (FSFI)Pain before2.1 units on a scaleStandard Deviation 2.3
Usual CareFemale Sexual Function Index (FSFI)Arousal after2.3 units on a scaleStandard Deviation 2.2
Usual CareFemale Sexual Function Index (FSFI)Orgasm before2.2 units on a scaleStandard Deviation 2.3
Usual CareFemale Sexual Function Index (FSFI)Orgasm after2.3 units on a scaleStandard Deviation 2.1
Usual CareFemale Sexual Function Index (FSFI)Total before13.8 units on a scaleStandard Deviation 10.9
Usual CareFemale Sexual Function Index (FSFI)Desire before2.7 units on a scaleStandard Deviation 1.4
Usual CareFemale Sexual Function Index (FSFI)Satisfaction before2.8 units on a scaleStandard Deviation 1.9
Usual CareFemale Sexual Function Index (FSFI)Desire after2.6 units on a scaleStandard Deviation 1.5
Usual CareFemale Sexual Function Index (FSFI)Pain after2.8 units on a scaleStandard Deviation 2.4
Usual CareFemale Sexual Function Index (FSFI)Arousal before2.0 units on a scaleStandard Deviation 2.2
Usual CareFemale Sexual Function Index (FSFI)Satisfaction after3.4 units on a scaleStandard Deviation 1.8
Usual CareFemale Sexual Function Index (FSFI)Lubrication before1.6 units on a scaleStandard Deviation 2.2
Usual CareFemale Sexual Function Index (FSFI)Total after16.4 units on a scaleStandard Deviation 10.9
Usual CareFemale Sexual Function Index (FSFI)Lubrication after3.1 units on a scaleStandard Deviation 2.5
Secondary

O'Leary Sant Symptom Problem Index (OSPI)

The OSPI is a Interstitial cystitis (IC/BPS)-specific scale composed of the symptom index and problem index as well as a total, which sums the symptom and problem scores caused by IC/BPS. Symptom scores range from 0-21. Problem scores range from 0-16 Higher scores indicate a worse condition. Total scores range 0-37, with higher scores indicating a worse condition.

Time frame: Baseline and within 2 weeks of 8-week class ending

ArmMeasureGroupValue (MEAN)Dispersion
Mindfulness-based Stress Reduction (MBSR)O'Leary Sant Symptom Problem Index (OSPI)OSPI symptoms after12.5 units on a scaleStandard Deviation 4.8
Mindfulness-based Stress Reduction (MBSR)O'Leary Sant Symptom Problem Index (OSPI)OSPI Total After18.9 units on a scaleStandard Deviation 8.7
Mindfulness-based Stress Reduction (MBSR)O'Leary Sant Symptom Problem Index (OSPI)OSPI Problems before10.3 units on a scaleStandard Deviation 3.1
Mindfulness-based Stress Reduction (MBSR)O'Leary Sant Symptom Problem Index (OSPI)OSPI Total Before26.4 units on a scaleStandard Deviation 8.1
Mindfulness-based Stress Reduction (MBSR)O'Leary Sant Symptom Problem Index (OSPI)OSPI Problems after6.4 units on a scaleStandard Deviation 4
Mindfulness-based Stress Reduction (MBSR)O'Leary Sant Symptom Problem Index (OSPI)OSPI Symptoms before16.1 units on a scaleStandard Deviation 5.3
Usual CareO'Leary Sant Symptom Problem Index (OSPI)OSPI Problems after9.4 units on a scaleStandard Deviation 3.6
Usual CareO'Leary Sant Symptom Problem Index (OSPI)OSPI Total Before25.4 units on a scaleStandard Deviation 6.6
Usual CareO'Leary Sant Symptom Problem Index (OSPI)OSPI Total After24.0 units on a scaleStandard Deviation 5.6
Usual CareO'Leary Sant Symptom Problem Index (OSPI)OSPI symptoms after14.6 units on a scaleStandard Deviation 2.3
Usual CareO'Leary Sant Symptom Problem Index (OSPI)OSPI Problems before10.2 units on a scaleStandard Deviation 3.9
Usual CareO'Leary Sant Symptom Problem Index (OSPI)OSPI Symptoms before15.2 units on a scaleStandard Deviation 2.9
Secondary

Pain Self-Efficacy Scale (PSEQ)

The PSEQ is a scale describing how patients rate their abilities to complete daily activities. It is a 60 point scale (scores range from 0-60) composed of 10 questions. Higher numbers signify better functioning or less limit by disease. A total score is calculating by summing individual items.

Time frame: Baseline and within 2 weeks of 8-week class ending

ArmMeasureGroupValue (MEAN)Dispersion
Mindfulness-based Stress Reduction (MBSR)Pain Self-Efficacy Scale (PSEQ)PSEQ Before34.3 units on a scaleStandard Deviation 4.5
Mindfulness-based Stress Reduction (MBSR)Pain Self-Efficacy Scale (PSEQ)PSEQ After45.8 units on a scaleStandard Deviation 4.9
Usual CarePain Self-Efficacy Scale (PSEQ)PSEQ Before30.8 units on a scaleStandard Deviation 10.7
Usual CarePain Self-Efficacy Scale (PSEQ)PSEQ After33.5 units on a scaleStandard Deviation 9.3
Secondary

Short Form Health Survey (SF-12)

The short form health survey (SF-12) is a scale used to evaluate chronic conditions. It is composed of a mental component and physical component. Each is made up of 12 questions totaling a score of 100 points. A zero score indicates the lowest level of health measured and 100 indicates the highest level of health.

Time frame: Baseline and within 2 weeks of 8-week class ending

ArmMeasureGroupValue (MEAN)Dispersion
Mindfulness-based Stress Reduction (MBSR)Short Form Health Survey (SF-12)PCS After46.3 units on a scaleStandard Deviation 10.3
Mindfulness-based Stress Reduction (MBSR)Short Form Health Survey (SF-12)MCS Before39.0 units on a scaleStandard Deviation 4.5
Mindfulness-based Stress Reduction (MBSR)Short Form Health Survey (SF-12)MCS After47.0 units on a scaleStandard Deviation 8.9
Mindfulness-based Stress Reduction (MBSR)Short Form Health Survey (SF-12)PCS Before46.5 units on a scaleStandard Deviation 8.6
Usual CareShort Form Health Survey (SF-12)PCS Before44.1 units on a scaleStandard Deviation 9.3
Usual CareShort Form Health Survey (SF-12)PCS After46.5 units on a scaleStandard Deviation 9.3
Usual CareShort Form Health Survey (SF-12)MCS After40.8 units on a scaleStandard Deviation 8.1
Usual CareShort Form Health Survey (SF-12)MCS Before36.6 units on a scaleStandard Deviation 6.9
Secondary

Visual Analog (VAS) Pain Scale

The VAS scale is a 10-point scale ranging from 0 (no pain) to 10 (unbearable pain). 0 is considered better while 10 is considered worse.

Time frame: Baseline and within 2 weeks of 8-week class ending

ArmMeasureGroupValue (MEAN)Dispersion
Mindfulness-based Stress Reduction (MBSR)Visual Analog (VAS) Pain ScaleVAS Before5.9 units on a scaleStandard Deviation 2.4
Mindfulness-based Stress Reduction (MBSR)Visual Analog (VAS) Pain ScaleVAS After4.9 units on a scaleStandard Deviation 2
Usual CareVisual Analog (VAS) Pain ScaleVAS Before5.7 units on a scaleStandard Deviation 2.2
Usual CareVisual Analog (VAS) Pain ScaleVAS After4.6 units on a scaleStandard Deviation 2.1

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026